In the Western world the incidence of renal cell carcinoma (RCC) has been increasing for several decades.
The highly conserved WNT pathway is involved in the transduction of signals from the cell surface to the nucleus, and it is known to play a key role in embryonic development, adult tissue maintenance and tumourigenesis (Klaus & Birchmeier, 2008).
We assessed temporal shifts in the frequency of risk factors for patients with metastatic renal cell carcinoma in a multicenter, international data set.
immatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA
The phase 3 IMPRINT trial* is designed to show an overall survival benefit with IMA901 in combination with sunitinib, standard first-line therapy in comparison to sunitinib alone in patients with metastatic and/or locally advanced RCC. The secondary endpoints include immune response to the peptides contained in IMA901, progression-free survival, safety and tolerability.
Locally Recurrent Renal Cancer: Surgical Interventions and Prognosis in a Challenging Clinical Setting
Local tumor recurrence (LR) in renal cancer poses challenges to surgical and medical oncologists alike. In a historic context, LR in the resection bed or adjacent tissues after a prior radical nephrectomy (RN) was a rare event.
For any nonprofit cancer organization, a key challenge is how to balance the enormous task of supporting cancer patients with the latest information about current treatments while helping to advance the search for new breakthroughs in therapeutic options.
Healthcare costs are increasing and the price of healthcare is causing an ever more serious problem (for people who do not have insurance to access basic healthcare and companies providing a health benefit to their employees) making healthcare systems that offer Âfree careÂ seem attractive. Let us not forget that this problem exists in part because of research to date that has yielded choices.
Join KidneyCancer.ME to meet other families near you that are dealing with renal cancers. Sign up with Facebook. Once you're a part of the newest virtual community for those whose lives have been touched by kidney cancer (including Wilms tumor that affects children), you'll be able to see yourself and others on a map. Then, you may connect with others in your neighborhood or across the nation that are dealing with renal cancers. In the Forum section you can initiate topical discussions on any aspect of kidney cancer that interests you. Get on the map today at www.KidneyCancer.Me.
Lpath, Inc. (OTCQB: LPTND), the industry leader in bioactive lipid-targeted therapeutics, has received confirmation that its application to list the company's common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group.
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines
Multitargeted tyrosine kinase inhibitors (TKIs) (such as Sunitinib and Sorafenib) and mTOR inhibitors (such as Temsirolimus) are effective in treating metastatic clear-cell renal cell carcinoma (CCRCC), by acting on different pathways in both tumour and endothelial cells. A study of their combined effect could be of major interest.
|NeonCRM by Neon One|